ZURICH/BERLIN, June 17(Reuters) - The Swiss blue-chip SMI was seen opening 0.1% lower at 10,023 points on Wednesday, according to premarket indications from bank Julius Baer.
Here are some of the main factors that may affect Swiss stocks:
The U.S. Food and Drug Administration (FDA) said it had approved Ilaris injection for treatment of active Still’s disease, including adult-onset Still’s disease.
CEO Roger Herzog tells Finanz und Wirtschaft paper the property company is doing well. “I see no indication, also not because of COVID-19, that we would have to change our dividend policy,” he says.
* Novartis said its Cosentyx drug had received the FDA approval for new indication to treat active non-radiographic axial spondyloarthritis.
* Swissquote Group Holding SA: net revenues for the first half year are now estimated over CHF 160 million (h1-2019: 112.2 million); H1 pre-tax profit should exceed CHF 56 million (h1-2019: 25.1 million)
* Helvetia Holding AG: Helvetia and Raiffeisen have agreed to end their long-term and exclusive sales cooperation by mutual agreement on December 31, 2020
* Santhera said it completed a capital increase, issuing 870,000 reserve shares
* Achiko announced a $4 million capital increase.
* Blackstone Resources said it had sold exploration interests for 22 million Sfr.
* Metall Zug said a scheduled for spin-off of V-Zug had been less significantly affected by the impact of COVID-19 pandemic.
* Swiss Prime Site AG: Martin Kaleja appointed CEO of Swiss Prime Site Immobilien and member of the executive board of Swiss Prime Site
* Ascom Holding AG: secures U.S. healthcare contract worth CHF 1.2 million.
* SIX Exchange Regulation approves BFW Liegenschaften’s delisting application
No major economic data scheduled
Reporting by Zurich newsroom and Berlin Speed Desk